Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019
(PR Web Via Acquire Media NewsEdge) Albany, NY (PRWEB) July 12, 2014
"Critical Care Therapeutics in Major Developed Markets to 2020 - New and Late-Stage Four-Factor PCCs and Recombinant Products to Drive Market," which provides in-depth analysis of the critical care market in the US, UK, France, Germany, Italy, Spain, Japan and Canada. The report provides an estimation of market size for 2013, along with market forecasts to 2020. It covers critical care indications that are being treated using the five major plasma-derived products of albumin, anti-thrombin concentrates, factor XIII concentrates, fibrinogen concentrates, and prothrombin complex concentrates. The total value of the critical care market in the major developed markets was estimated at $1.8 billion in 2013 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 4.7% to $2.5 billion in 2019.
View Full Report With Complete TOC or Request Sample Of This Report at http://www.researchmoz.us/critical-care-therapeutics-in-major-developed-markets-to-2020-new-and-late-stage-four-factor-pccs-and-recombinant-products-to-drive-market-report.html.
This growth is attributed to the recent approval of new factor concentrates in the US that are expected to witness increasing uptake in the forecast period. Factor concentrates are increasingly preferred due to their lower infection risks over older alternatives such as FFP and cryoprecipitate in critical care settings. The US accounts for the largest share (41%) of the global critical care market and is expected to post high growth at a CAGR of 7.5% until 2020. KCentra, the first four-factor PCC in the US, and Tretten, the first recombinant FXIII concentrate, were approved in 2013 and are expected to witness good uptake in the forecast period. Two additional factor concentrates approved in the US in 2009 – RiaStap (human fibrinogen concentrate) and ATryn (recombinant AT concentrate) – are also expected to increase their uptake, which will contribute to market growth. With no new significant launches in the forecast period, the European market is estimated to witness much slower growth, with the UK at a CAGR of 3.0%, France at 2.5%, Germany and Spain both at 2.3%, and Italy at 2.0%
Browse All Published Reports by GBI at http://www.researchmoz.us/publisher/gbi-research-2.html.
The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in critical care in the eight major developed markets of the US, UK, France, Germany, Italy, Spain, Japan and Canada.
The report includes:
• A brief introduction to the five major plasma-derived products in critical care and the indications that they are being used to treat, as well as disease overview, epidemiology, other treatment options, and treatment patterns -Analysis of major marketed products in critical care, covering product performance in terms of the safety and efficacy of recent approvals
-A review of the critical care pipeline, including individual analysis of promising late-stage pipeline drugs that are most likely to enter the market during the forecast period
-Multi-scenario forecasts of the critical care market over the 2013–2020 period in the eight major developed markets
-Key drivers and restraints that have had and are expected to have a significant impact on the market
-An overview of major licensing and co-development agreements that could affect growth trends
View All Countrywise Market Research Reports at http://www.researchmoz.us/country.html.
Reasons to Buy
The report will enhance your decision-making capability by allowing you to:
-Align your product portfolio to markets with high growth potential
-Develop market entry and expansion strategies by identifying the regions and therapeutic segments poised for strong growth
-Devise effective, tailored strategies for each country through the understanding of key drivers and barriers in the critical care drugs market
-Develop key strategic initiatives based on an understanding of key focus areas and leading companies
-Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships
Related Reports -
Breast Cancer Therapeutics in Major Developed Markets to 2020 - Approval of Novel Therapies to Support Continued Dominance of HER2 Targeted Drugs
The breast cancer therapeutics market in the eight major markets – The US, The UK, France, Germany, Spain, Italy, Japan and Canada – was worth $9.2 billion in 2013, and is expected to grow at a Compound Annual Growth Rate (CAGR) of 5.1% to $13.1 billion by 2020. The US had the largest market in 2013, valued at $5.5 billion, equivalent to a global share of 59%, followed by Japan with $871.5m or 9.4% and Italy with $668.5m or 7.2%. Canada had the lowest market share and value of the leading eight at 2.9% and $268.4m, but is expected to witness rapid growth over the forecast period with a CAGR of 6.7%. This will only be surpassed by Japan, which is expected to witness growth at a CAGR of 6.9%.
View Full Report With Complete TOC or Request Sample of This Report at http://www.researchmoz.us/breast-cancer-therapeutics-in-major-developed-markets-to-2020-approval-of-novel-therapies-to-support-continued-dominance-of-her2-targeted-drugs-report.html.
Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2019 - Growth to Hinge on the Success of Personalized Vaccine Following Early Approval in Germany
In newly diagnosed patients, the current standard of care, comprising resection surgery, radiation therapy and chemotherapy with Merck's Temodar (temozolomide), has a maximum Overall Survival (OS) of 15 months and almost inevitable tumor recurrence. Current therapeutic options for recurrent GBM are Roche's Avastin (bevacizumab), carmustine and other chemotherapy drugs used off-label. However, they only offer limited OS benefit, leaving high unmet need in this patient segment. During the 2012–2019 forecast period, the GBM market is expected to grow rapidly from $305m to $583m.
View Full Report With Complete TOC or Request Sample of This Report at http://www.researchmoz.us/glioblastoma-multiforme-therapeutics-in-major-developed-markets-to-2019-growth-to-hinge-on-the-success-of-personalized-vaccine-following-early-approval-in-germany-report.html.
Anti-Hypertensive Therapeutics in Major Developed Markets to 2020 - Increased Uptake of Combination Therapies to Offset Effects of Key Patent Expiries
The report provides an estimation of market size for 2013, along with market forecast until 2020. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis. The value of the hypertension market in the major developed markets amounted to an estimated $40.0 billion in 2013 and is expected to decline during the forecast period at a negative Compound Annual Growth Rate (CAGR) of 0.9% to $37.6 billion in 2020, with growth expected from 2013 to 2017 at a CAGR of 2.6% and a decline thereafter.
View Full Report With Complete TOC or Request Sample of This Report at http://www.researchmoz.us/anti-hypertensive-therapeutics-in-major-developed-markets-to-2020-increased-uptake-of-combination-therapies-to-offset-effects-of-key-patent-expiries-report.html.
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
Browse Market Research Articles at https://www.linkedin.com/today/author/173774513.
Read the full story at http://www.prweb.com/releases/2014/07/prweb12011902.htm
(c) 2014 PRWEB.COM Newswire
[ Back To TMCnet.com's Homepage ]